 Connection
David Moreno to Multiple Myeloma
This is a "connection" page, showing publications David Moreno has written about Multiple Myeloma.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
3.224 |
|
|
|
-
Moreno DF, Oriol A, de la Rubia J, Hern?ndez MT, I?igo MB, Palomera L, de Arriba F, Gonz?lez Y, Teruel AI, Pardo JL, L?pez de la Gu?a A, Sampol A, R?os-Tamayo R, Sureda A, Guti?rrez NC, Calasanz MJ, Ramos MLM, Mateos MV, San Miguel J, Lahuerta JJ, Blad? J, Rosi?ol L. Is t(11;14) Always a Standard-Risk Cytogenetic Abnormality? Results From GEM05MENOS65 and GEM2012 PETHEMA/GEM Transplantation Trials. Clin Lymphoma Myeloma Leuk. 2025 Jul; 25(7):494-504.
Score: 0.832
-
Moreno DF, Clap?s V, Soler JA, Gonz?lez-Montes Y, Gironella M, Motll? C, Granell M, Abella E, Garc?a-Pintos M, Garc?a-Gui??n A, Cabezudo E, Blad? J, Rosi?ol L. Real-World Evidence of Daratumumab Monotherapy in Relapsed/Refractory Multiple Myeloma Patients and Efficacy on Soft-Tissue Plasmacytomas. Clin Lymphoma Myeloma Leuk. 2022 08; 22(8):635-642.
Score: 0.686
-
Rodr?guez-Lobato LG, de Daniel A, Pereira A, Fern?ndez de Larrea C, Tovar N, Cibeira MT, Moreno DF, Mateos JM, Llobet N, Carcelero E, Mun?rriz D, Blad? J, Rosi?ol L. Attrition rates and treatment outcomes in multiple myeloma: real-world data over a 40-year period. Blood Cancer J. 2025 May 26; 15(1):103.
Score: 0.213
-
Zugasti I, Tormo-Ratera M, Oliver-Cald?s A, Soler-Perromat JC, Gonz?lez-Calle V, Moreno DF, Caba?as V, L?pez-Mu?oz N, Bartolom?-Solanas ?, Espa?ol-Rego M, Reguera-Ortega JL, Rosi?ol L, L?pez-Corral L, Tovar N, Rodr?guez-Lobato LG, Alvarez Perez RM, Varea S, Olesti E, Gomez-Grande A, Frutos L, Tamayo P, Juan M, Moraleda JM, Urbano-Ispizua ?, Gonz?lez-Navarro EA, Mart?nez-L?pez J, Mateos MV, Tom?s X, Setoain X, Fern?ndez de Larrea C. Clinical impact of [18F]FDG-PET/CT in ARI0002h treatment, a CAR-T against BCMA for relapsed/refractory multiple myeloma. Blood Adv. 2025 Feb 11; 9(3):571-582.
Score: 0.209
-
Battram AM, Ma??-Pujol J, Moreno DF, Oliver-Cald?s A, Carpio J, Cardus O, Rodr?guez-Lobato LG, Urbano-Ispizua ?, Fern?ndez de Larrea C. Genetic disruption of Blimp-1 drastically augments the antitumor efficacy of BCMA-targeting CAR T cells. Blood Adv. 2025 Feb 11; 9(3):627-641.
Score: 0.209
-
Lozano E, Mena MP, Garrabou G, Card?s O, D?az T, Moreno DF, Ma??-Pujol J, Oliver-Cald?s A, Battram A, Tovar N, Cibeira MT, Rodr?guez-Lobato LG, Blad? J, Fern?ndez de Larrea C, Rosi?ol L. Increased PVR Expression on Bone Marrow Macrophages May Promote Resistance to TIGIT Blockade in Multiple Myeloma. Clin Cancer Res. 2024 Sep 03; 30(17):3944-3955.
Score: 0.202
-
Oliver-Caldes A, Espa?ol-Rego M, Zabaleta A, Gonz?lez-Calle V, Navarro-Vel?zquez S, Inog?s S, de Cerio AL, Caba?as V, L?pez-Mu?oz N, Rodr?guez-Otero P, Reguera JL, Moreno DF, Mart?nez-Cibrian N, L?pez-Corral L, P?rez-Amill L, Martin-Antonio B, Rosi?ol L, Cid J, Tovar N, S?ez-Pe?ataro J, L?pez-Parra M, Olesti E, Guill?n E, Varea S, Rodr?guez-Lobato LG, Battram AM, Gonz?lez MS, S?nchez-Salinas A, Gonz?lez-Navarro A, Ortiz-Maldonado V, Delgado J, Pr?sper F, Juan M, Mart?nez-L?pez J, Moraleda JM, Mateos MV, Urbano-Ispizua ?, Paiva B, Pascal M, Fern?ndez de Larrea C. Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma. Clin Cancer Res. 2024 May 15; 30(10):2085-2096.
Score: 0.198
-
Jim?nez-Segura R, Rosi?ol L, Cibeira MT, Fern?ndez de Larrea C, Tovar N, Rodr?guez-Lobato LG, Blad? E, Moreno DF, Oliver-Cald?s A, Blad? J. Paraskeletal and extramedullary plasmacytomas in multiple myeloma at diagnosis and at first relapse: 50-years of experience from an academic institution. Blood Cancer J. 2022 09 16; 12(9):135.
Score: 0.177
-
Oliver-Caldes A, Jim?nez R, Espa?ol-Rego M, Cibeira MT, Ortiz-Maldonado V, Quintana LF, Castillo P, Guijarro F, Tovar N, Montoro M, Benitez-Ribas D, Bataller A, Gonz?lez-Navarro EA, Cid J, Lozano M, Perez-Amill L, Martin-Antonio B, Mena MP, Moreno DF, Rodr?guez-Lobato LG, Campistol JM, Calvo G, Blad? J, Rosi?ol L, Juan M, Pascal M, Urbano-Ispizua A, Fern?ndez de Larrea C. First report of CART treatment in AL amyloidosis and relapsed/refractory multiple myeloma. J Immunother Cancer. 2021 12; 9(12).
Score: 0.167
-
Isola I, Bras?-Maristany F, Moreno DF, Mena MP, Oliver-Calders A, Par? L, Rodr?guez-Lobato LG, Martin-Antonio B, Cibeira MT, Blad? J, Rosi?ol L, Prat A, Lozano E, Fern?ndez de Larrea C. Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease. Front Immunol. 2021; 12:792609.
Score: 0.167
-
Rodr?guez-Lobato LG, Pereira A, Fern?ndez de Larrea C, Cibeira MT, Tovar N, Jim?nez-Segura R, Moreno DF, Oliver-Cald?s A, Rosi?ol L, Blad? J. Real-world data on survival improvement in patients with multiple myeloma treated at a single institution over a 45-year period. Br J Haematol. 2022 02; 196(3):649-659.
Score: 0.165
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|